Amgen (AMGN) Capital Expenditures (2009 - 2026)

Amgen's Capital Expenditures history runs 18 years deep, the most recent figure standing at $712.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 73.24% year-over-year to $712.0 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 69.07% YoY), while the FY2025 annual figure was $1.9 billion, up 69.53% from the prior year.
• Capital Expenditures was $712.0 million for Q1 2026 at Amgen, up from $642.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $712.0 million in Q1 2026 to a low of $160.0 million in Q3 2022.
• Historically, Capital Expenditures has averaged $336.1 million across 5 years, with a median of $271.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures tumbled 33.88% in 2022, then soared 81.05% in 2023.
• A 5-year view of Capital Expenditures shows it stood at $340.0 million in 2022, then declined by 26.76% to $249.0 million in 2023, then jumped by 49.0% to $371.0 million in 2024, then surged by 73.05% to $642.0 million in 2025, then advanced by 10.9% to $712.0 million in 2026.
• The last three Capital Expenditures figures came in at $712.0 million (Q1 2026), $642.0 million (Q4 2025), and $436.0 million (Q3 2025), per Business Quant data.